217 related articles for article (PubMed ID: 30833679)
1. Axitinib-ICIs boost the RCC armamentarium.
Romero D
Nat Rev Clin Oncol; 2019 Apr; 16(4):207. PubMed ID: 30833679
[No Abstract] [Full Text] [Related]
2. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma.
Zhu J; Zhang T; Wan N; Liang Z; Li J; Chen X; Liang W; Jiang J
Immunotherapy; 2020 Dec; 12(17):1237-1246. PubMed ID: 32878521
[No Abstract] [Full Text] [Related]
4. [First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].
Rexer H; Bedke J
Urologe A; 2017 Mar; 56(3):385-386. PubMed ID: 28246756
[No Abstract] [Full Text] [Related]
5. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Future Oncol; 2021 Jan; 17(3):241-254. PubMed ID: 33016119
[TBL] [Abstract][Full Text] [Related]
6. Fatal autoimmune myocarditis with anti-PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer.
Berner AM; Sharma A; Agarwal S; Al-Sam S; Nathan P
Eur J Cancer; 2018 Sep; 101():287-290. PubMed ID: 30017380
[No Abstract] [Full Text] [Related]
7. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
Soleimani M; Nappi L; Kollmannsberger C
Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478
[TBL] [Abstract][Full Text] [Related]
8. Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma.
Yang Y; Huang H; Li T; Gao Q; Song Y; Wang Z
Front Immunol; 2021; 12():728750. PubMed ID: 34764951
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab and erlotinib show promise for kidney cancer.
Lindsey H
Lancet Oncol; 2006 Jan; 7(1):15. PubMed ID: 16408368
[No Abstract] [Full Text] [Related]
10. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
[No Abstract] [Full Text] [Related]
11. [Risk-adapted therapy for metastatic renal cell carcinoma].
Grimm MO; Leucht K; Foller S; Grünwald V
Urologe A; 2020 Feb; 59(2):155-161. PubMed ID: 32006060
[TBL] [Abstract][Full Text] [Related]
12. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
[TBL] [Abstract][Full Text] [Related]
13. In focus: bevacizumab for renal cell carcinoma.
Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
[No Abstract] [Full Text] [Related]
14. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
Cai W; Cai B; Zhou J; Chen Y; Zhang J; Huang Y; Xue W; Huang J
Cancer Commun (Lond); 2019 Oct; 39(1):56. PubMed ID: 31601263
[No Abstract] [Full Text] [Related]
16. Combination therapy in patients with metastatic renal cell carcinoma.
Escudier BJ
Clin Adv Hematol Oncol; 2010 Oct; 8(10):665-6. PubMed ID: 21317861
[No Abstract] [Full Text] [Related]
17. Pembrolizumab + axitinib beyond first-line therapy for mRCC.
Thomas T
Nat Rev Urol; 2023 Mar; 20(3):131. PubMed ID: 36797430
[No Abstract] [Full Text] [Related]
18. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
Phillips T; Brunvand M; Chen AI; Essell J; Chiappella A; Diefenbach C; Cheng J; Ramies D; Hirata J; Morschhauser F; Flinn IW
Am J Hematol; 2022 Jan; 97(1):E24-E27. PubMed ID: 34731510
[No Abstract] [Full Text] [Related]
19. Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor.
Ornstein MC; Wood LS
Adv Ther; 2023 Sep; 40(9):3599-3609. PubMed ID: 37233877
[No Abstract] [Full Text] [Related]
20. Intestinal Pneumatosis: A Manifestation of Rarely Reported Axitinib-Associated Necrotizing Enterocolitis.
Akhtar K; Zayac A; Lemke S
Am J Ther; 2018; 25(6):e763-e765. PubMed ID: 29746290
[No Abstract] [Full Text] [Related]
[Next] [New Search]
